Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imiquimod + Sci-B-Vac
- Development stage
- Approved
- Lead developer
- The University of Hong Kong
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Topical
01
Overview
ID HBVv refers to a specific therapeutic regimen involving the intradermal (ID) administration of the Hepatitis B Virus vaccine (HBVv) Sci-B-Vac™ in combination with topical imiquimod. Sci-B-Vac is a recombinant, third-generation vaccine derived from mammalian cells that contains all three hepatitis B surface antigens (S, pre-S1, and pre-S2), offering a broader antigenic profile than conventional single-antigen vaccines. Imiquimod, a synthetic Toll-like receptor 7 (TLR7) agonist, is applied topically to the injection site immediately before vaccination to serve as an immune adjuvant. This combination is designed to enhance immunogenicity and induce seroconversion in populations that are typically hyporesponsive to standard vaccination, such as patients with occult hepatitis B infection (OBI). The regimen was evaluated in a Phase 2/3 clinical trial (NCT03307902) led by The University of Hong Kong.
- Brand names
- Sci-B-VacPreHevbrioAldara
- Other names
- Intradermal Hepatitis B Vaccination with Imiquimodimiquimod-adjuvanted Sci-B-Vac
02
Targets
Pre-S2 (Hepatitis B virus Pre-S2 envelope region)preS1 (HBV presurface protein 1)TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)
Beyond the preview
Go deeper on imiquimod + Sci-B-Vac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imiquimod + Sci-B-Vac.